Copyright
©The Author(s) 2016.
World J Nephrol. Sep 6, 2016; 5(5): 398-417
Published online Sep 6, 2016. doi: 10.5527/wjn.v5.i5.398
Published online Sep 6, 2016. doi: 10.5527/wjn.v5.i5.398
Table 1 Different therapeutic interventions used to prevent or withhold vascular calcification progression
| CKD stage | Risk factor | Type off interference | Outcome | Ref. |
| Traditional Risk factors | ||||
| G1-G5 | Cigarette smoking | Cessation | No evidence | [202] |
| G1-G5 | Overweight | Decrease calorie intake | No evidence | [202] |
| G1-G5 | Sedentary life | Muscle excercise | No evidence | [202] |
| G1-G5 | Diabetes mellitus | Blood sugar control | Improves survival | [204] |
| Delays CKD progression | [205] | |||
| G1-G5 | Systemic hypertension | Blood pressure control | Delays CKD progression | [206] |
| G1-G5 | Dyslipidemia | Statins | Decreased CV morbidity | [221] |
| CKD Related Risk factors | ||||
| G2-G5 | ↑ | Dietary phosphate restriction | ↓ FGF23 | [222] |
| G3b-G4 | Hyperphosphatemia | Sevelamer | ↓ VC, ↓ mortality | [226] |
| G5 | Preemptive kidney Tx | ↓ VC, ↓ mortality | [52,295] | |
| Incident G5D | Hyperphosphatemia | Sevelamer | ↓ VC, ↓ mortality (borderline) | [231] |
| Prevalent G5D | Hyperphosphatemia | Sevelamer or L.C. | ↓ VC | [232,240,251] |
| Prevalent G5D > 65 yr | Hyperphosphatemia | Sevelamer or L.C. | ↓ VC, ↓ mortality | [240,251] |
- Citation: Sharaf El Din UAA, Salem MM, Abdulazim DO. Vascular calcification: When should we interfere in chronic kidney disease patients and how? World J Nephrol 2016; 5(5): 398-417
- URL: https://www.wjgnet.com/2220-6124/full/v5/i5/398.htm
- DOI: https://dx.doi.org/10.5527/wjn.v5.i5.398
